However, the risk of ICD is lower with levodopa,41 likely due to differences in receptor activation profiles: levodopa leads to dopamine release, which in turn would tend to activate both D1Rs and D2Rs, whereas dopamine D2R agonists like PPX selectively target D2Rs (and D3Rs). This evidence concerns the gene DRD2 and impulse control disorder.